www.biopharminternational.com Emerging Therapies eBook September 2023 BioPharm International
®
23
Vaccines
resources needed for manual processes, and the time
taken to produce single therapies. Funding for these
trials can be a limiting factor in mRNA cancer vaccine
clinical development, particularly in the current global
economic environment. Economic pressure is most im-
pactful for emerging biopharma/biotechnology com-
panies but impacts large pharmaceuticals as well.
As the potential of mRNA vaccines for cancer be-
comes increasingly clear, mRNA vaccine clinical
development has seen an inf lux of f unding f rom
government sources and investors. For example,
the UK government announced a collaboration with
BioNTech aimed at boosting research into cancer vac-
cines (8). However, in the long run, making mRNA
vaccines for cancer accessible to broader populations
will require bringing down the cost of manufacturing
single therapies.
Conclusion
While it is premature to say which evolving efforts
in mRNA cancer vaccines will be most fruitful, all
will benefit from accounting for key logistical con-
siderations, including patient recr uitment, man-
ufacturing, reg ulator y compliance, and f unding.
Preliminar y successes of mRNA vaccines suggest
they will soon be an invaluable tool in the immu-
nology toolbox.
References
1. Moderna and Merck Announce mRNA-4157/V940,
a n Invest igat iona l Persona l ized m R NA Ca ncer
Vaccine, in Combination With KEYTRUDA(R) (pem-
brolizumab), was Granted Breakthrough Therapy
Designation by the FDA for Adjuvant Treatment of
Patients With High-Risk Melanoma Following Com-
plete Resection. Moderna. Accessed April 6, 2023.
2. Rojas LA, Sethna Z, Soares KC, et al. Personalized
RNA neoantigen vaccines stimulate T cells in pan-
creat ic ca ncer. Nat ure. 2023;618(7963):14 4-150.
doi:10.1038/s41586-023-06063-y
3. Barbier AJ, Jiang AY, Zhang P, Wooster R, Ander-
son DG. The clinical progress of mRNA vaccines and
immunotherapies. Nat Biotechnol. 2022;40(6):840-
854. doi:10.1038/s41587-022-01294-2
4. Ingels J, De Cock L , Mayer RL , et al. Small-Scale
Manufacturing of Neoantigen-Encoding Messenger
RNA for Early-Phase Clinical Trials. Cytotherapy.
2022;24(2):213-222. doi:10.1016/j.jcyt.2021.08.005
5. Ribas A. Adaptive Immune Resistance: How Can-
cer Protects from Immune Attack. Cancer Discov.
2015;5(9):915-919. doi:10.1158/2159-8290.CD-15-0563
6. Mackensen A. BNT211-01: A Phase I Trial to Evalu-
ate Safety and Efficacy of CLDN6 CAR T Cells and
CLDN6-Encoding mRNA Vaccine-Mediated In Vivo
Expansion in Patients with CLDN6-Positive Ad-
vanced Solid Tumours. In: ; 2022.
7. Vuksanaj K. Next-Generation Cancer Vaccines Get
Personal. GEN - Genetic Engineering and Biotech-
nology News. Published August 9, 2022. Accessed
June 22, 2023.
8. New Partnership to Boost Research into Vaccines
for Cancer. GOV.UK. Accessed July 24, 2023. ■
Jeff Fischer
co-founder and president,
Longhorn Vaccines
and Diagnostics
Evaluating the Vaccine Marketplace
Pharmaceutical Technology
®
presents the Drug
Solutions podcast, where the editors chat with
industry experts from across the pharmaceutical and
biopharmaceutical supply chain. Join us as experts
share insights into your biggest questions—from the
technologies, to strategies, to regulations related to the
development and manufacture of drug products.
In this episode of the Drug Solutions podcast, one
of the staff members of Pharmaceutical Technology
®
speak with Jeff Fischer, co-founder and president of
Longhorn Vaccines and Diagnostics, on the history and
ongoing development of both protein- and mRNA-based
vaccines. Topics of discussion include recent vaccine
approvals, the broader state of the vaccine industry, and
ideal use cases for both vaccine formulations.
For more podcast
episodes, visit PharmTech.com!